Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guess Mith was right about the PR LOL
The thrill is gone, as BB King would say. The downward trajectory of the PPS since the 2.49 you refer to has been consistent and relentless, with only an occasional up tick (MM manipulation lowman?) to keep die hard longs actively and wistfully clamoring for a return to the good ol' days of Don and Frankie D and big Rich A.
For every white knight there's 10000 or more companies in distress waiting to saved. As for convertibles, we're trending close to the area where not even those leeches would sign over any money given the uncertainty of CTGI's current debt obligations.
The script here was made clear for all to see- follow the bread crumbs back a few years (it begins with the lawsuit news neatly tucked into the CE mark PR, then La Jolla, then the pinks, etc, etc, etc) and today's pathetic PPS makes perfect sense. That CTGI finds itself where it is today is no surprise to anyone but the ostriches with the longest necks.
Gotta' trust the DD, not the pump, no matter how much you want to believe.
Still holding 1.12 shares as well, but sold CCME waaaayyyyyy too early. Fernando's got the right idea with the compound gains; any other hidden gems in the sector that folks are eyeballing?
I took a starter in CLGZ last week.
GLTA
While I wouldn't expect to see any gains in the pps anytime soon, the CC left me feeling that CTGI will rise back up one day, and be worth a few coins
And the beat goes on..... It's worth a few coins now.....3 to be exact, lol.
Guess extrinsic was right, eh?
Wow. It's come to this: the CEO pandering on IHUB for $$ to pay the light bills. I've been involved with other companies whose CEOs have posted on IHUB and for the vast majority, the grim reality is that they didn't make it. Can't you cut a deal with Piazza to get LTC up and running or is he just waiting for it to fall into his lap when the first liens are issued?
Good luck to you Bruce. Gone are the days when a few million in seed money was a well written PR away. You'll be working hard to find 1/2 that amount now, given the economic climate and the time gap between the ink drying on the check and CTGI producing any revenue. This board, as you know, has been amazingly dedicated to seeing the success of first DR and now yourself. I doubt that collectively, there's much $$ left here for CTGI at this point.
Refresh my memory: how much $$ did Pfizer advance to HDVY?
I also wonder why anyone would think the next ten years would be any different.
Maybe try emailing Quest and Abbott with your query....
IMGG probably needs a class III 510 instead of class II as they had hoped. This means clinical trials and lots of $$. They have none.
Nice looking rebound play if you can wait for the additional trials. The FDA's concerns are more a question of BIOD's testing process rather than any over riding concern about Linjeta IMO.
GLTA
Recently, lowman referred to "the mess DR left behind" and aptly so
He also said this: CTGI would've been diluted down bigtime if it weren't for insiders' positions.
Hard to reconcile dumping on DR's ghost and trumpeting up the company's amazing share structure and inside holdings at the same time.
With regard to insider holdings, all we know lately is that Bruce tossed 5K at the the company and filed a form 4 so that the world would know all about it.....didn't bother filing or PR'ing the 25 million share dilution early this year....still uncertain at what price those shares were sold....
The rest is hidden in pinkness.
10k starter at .437
More stink bids in in case others get impatient.
in for a 100k starter. Rollover from DYER $$
Nice bit of trading there! Hope you had a ton of shares!
This run's dome IMO, at least until the new company puts out a few q's of audited financials.
The volume on the last big run wasn't massive and it's gonna' be a lot less with the new SS.
I'm still waiting for a market to develop with CDBH, my previous Meuse shell that RM'ed into a Chinese company. That RM was months ago. It's been dead money since. GLTY
Here's one thought: the share price upswing was engineered with a certain price in mind so that when the RS happens, the Co will be better positioned for an uplisting.
Mission accomplished.
SLRW please
....until you have to sell
BIOD
the India data has been weighing upon the share price. That's the bearish argument. The bullish one is that the FDA accepted the NDA even with the India data.
Accepting and approving are 2 totally different matters. I can't see the FDA giving full and unconditional approval to anything but a perfectly executed study with top line results. We shall see.
Thanks for that. Sounds like nothing too revealing in the meeting. Still a waiting game outside the powers of HDC. Good there was no increase in A/S.....
DYER up 1400% today. All out here from my 00 shares. Meuse strikes again!
DYERE 8k out:
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7505903
1 for 20 R/S for this shell.
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7472482
Filings have been coming quickly and the PPS has run from .01 to .05 in the past 10 days on around a million shares per day.
Looks like the new CEO just resigned from the BOD of SHNL
http://biz.yahoo.com/e/101008/shnl.ob8-k.html
Looks like SHNL has been pretty dormant since its RM into the shell
http://biz.yahoo.com/e/100816/shnl.ob10-q.html
A quick look at the 1 year chart for SHNL doesn't exactly fill one with excitement:
http://www.otcmarkets.com/stock/SHNL/quote
Still digging to find some 411 on the CEO;s current biz, but real estate in the PRC is a pretty happening field to be prospecting in these days.
GLTY
ALXA was torpedoed by the FDA for safety issues in Phase I, even though these issues were non-existent in later trials.
To me the FDA's message is clear: any question raised at any point in any trial makes the drug unprovable.
How can the FDA overlook the faulty India results? Even if the company has provided sufficient data, IMO it's a huge gamble to think that the FDA would want to set a precedent by approving a drug that has ANY issues at any stage of testing.
Best case scenario: conduct the trial again and re-submit when complete.
Review the last PR for an answer to your question: CSMG will not get LTC to the market in the future. Piazza and company may get LTC to market if CSMG ponies up some cash. If that were to happen, you're stake in LTC would be "significantly" reduced from it's current value.
Certainly seems like someone wants to accumulate a lot of shares. Still trying to DD the new CEO to get a handle on his past and the future direction of the new company.
Forgot to cancel a GTC order which filled at .046....290,000 shares....oh well, not a bad return on my .008's
Trying to DD the new CEO a bit to see what his track record is, but he seems to be moving the company along at a nice clip.
EXACTLY!! Why pay an IR firm $60K a yr for what?
I'll bite: you pay an IR firm 60k a year because you know you have a fantastic story, you know your cactus cigarettes are a big seller, you know you'll meet or exceed analysts' expectations and it's worth it to get the story out there.
Should the new LTC team confront the market with unflappable determination, outline their mission and their goals clearly, and keep shareholders regularly apprised of progress, they might hope to reverse the damage done by the old regime and restore a reasonable measure of value to the stock.
Too bad the new LTC team will own 75% of my (currently) company at that time....
Last post here on this topic for me. Let's look at your response:
Some of the patients’ cancer is located outside the lung cavity. Under the protocol submitted to the FDA, these patients must be excluded from the study. (note how the use of passive voice deftly sidesteps any accountability)
1. BMOD submitted the protocol to the FDA.
2. BMOD clearly did not follow the protocol it submitted or we would not be having this discussion.
WTF happened? It's that simple.
If these questions aren't important to you, so be it.
The question I posed is why as opposed to what happened. Big difference there.
Not me. I added here over the past couple of days. A rising tide.....
Not trying to get nasty Rain. No need for that...
Biomoda CEO Feeling Bullish About Pending Publication of Pilot Study
Biomoda, Inc. (OTCBB: BMOD) has been on many investors radar as a result of the Company’s innovative diagnostic test in lung-cancer which is performed in clinical reference laboratories using body-fluids. We, along with others, are anticipating positive results from the study, in large part based upon historical events. Below is a recent interview with John Cousins, President and CEO of Biomoda, in which he talks about what to expect in the short and long term.
BiomedReports: It has been a while since we first spoke to you. From a science and technology perspective, are there any developments to report?
Cousins: We have made significant progress since we last spoke. Perhaps the most important news for investors and cancer research overall is that we are completing our pilot study of Biomoda’s diagnostic assay for the early detection of lung cancer. Our pilot study, which is similar to the Phase II clinical studies required for new drugs, is the basis for moving forward with a pivotal study — the third and final phase of clinical study that leads to Food and Drug Administration (FDA) approval and commercialization. We are seeking FDA approval of our CyPath® assay as a Class III medical device. The requirements are quite rigorous. The results of our pilot study have not been announced, but we have stated our belief that the results will be statistically significant enough to move into a pivotal study.
And said it many times I might add
We are beginning work on the pivotal clinical study, including responding to questions from the FDA about the pilot study protocol and design, hiring a Clinical Research Organization (CRO) and establishing key collaborations that we will be announcing soon. We will continue research and development to optimize our assay, incorporating improvements such as automation that will lead to larger scale use at lower cost.
The pilot study analyzes samples from about 170 individuals including military veterans at high risk for cancer and individuals who have been diagnosed with cancer but had not yet begun treatment. I know you and others are very interested in knowing the ‘top-line’ results and summary data, and of course we will share those results when they are ready for release. Right now most important for us at Biomoda, and for our experts working on all phases of the clinical study, is the assurance that we have thoroughly analyzed the data and developed the most accurate assay possible. We want to provide an accurate picture of our assay and its performance. A rush to announce results might lead to increased funding opportunities in the immediate future and a short-term pop in the stock, but it can also lead to problems later on, when end points for the pivotal study are not met because the study data from the pilot study wasn’t sufficiently analyzed or the assay was not fully optimized based on lessons learned from
the pivotal study. We will not make those mistakes.
Real airtight operation to be sure
It’s worth mentioning that the Board of Directors elected Maria Zannes as Chairman of the Board. Maria has been the executive overseeing our pilot clinical trial
Why does this person still have a job?
and will continue to provide oversight throughout the pivotal trial. She’s working closely with Connie Dorian, our Vice President of Operations, in development of the assay and conduct of the clinical trials. They are a great team. Connie is an excellent clinical researcher, very detail oriented, and Maria provides a steady, long-term, focused and strategic vision as we move forward.
BiomedReports: Are Phase 2 results still coming this quarter?
Cousins: Biomoda chose one of the toughest cancers when we decided to develop our assay for the detection of lung cancer. We believe the assay platform will be applicable for many cancers. We are nearing completion of the pilot clinical study data analysis and preparing for publication of the results.
Are you honestly going to tell me that this quote in any way suggests the possibility of a flawed test?
We expect results of the pilot clinical study will be sufficient to launch the pivotal trial. We are designing the pivotal study on the foundation of the pilot study and adherence to the FDA’s rigorous requirements. We have a number of steps to complete before the pivotal can begin, including submission of a Pre-IDE to the FDA, the Agency’s response and, if necessary our follow-up to FDA comments. Our pivotal study will be a multi-state, multi-site study. It’s no surprise to anyone who follows our company that we are looking at Ohio and Nebraska as potential sites, and we intend to investigate sites and funding in Texas. I think researchers in those states are awaiting results of our pilot study.
BiomedReports: How is the development of Phase 3 registration coming along? When do you expect to enroll patients? Any developments on money to fund the trial via Nebraska or Ohio?
Cousins: New Mexico provided an excellent model for funding. Biomoda is headquartered in a progressive state for research. We have two national laboratories that conduct impressive research, and, in fact, Biomoda’s technology began at Los Alamos National Laboratory. Our legislature has been very supportive of our veterans who participated in the pilot study. There are other states, including Ohio and Nebraska that have shown an interest in the potential of our technology and are waiting for results of the pilot study.
Hence my point about state funding....guess that money will be waiting a while longer.
FWIW, I follow and respect your DD and board Rain. More importantly I've made money from your picks, lol. I've done my DD here as well. Clearly we've reached different conclusions, but the above words are straight from the horse's choppers.
LOL, emphasis and repetition are old bedfellows. Your response addresses the manner and not the meat of my post.... 'nuff said.
Things quietly down nicely.....most of the more vocal complainers have headed for the exits chasing another rainbow.
I think the company has a lot of "fool me once" to overcome now- the past 6 months were giddy with Cousin's optimism and promise (see PR's and ibox). It's going to take more than that this time around IMO. We still don't really know why the study was bungled, who identified the bungle and how different people responded to the bungle. Nothing undermines investor confidence like the double whammy of a lack of transparency coupled with a lack of success. There can certainly be no more "benefit of the doubt" for Cousins, who hasn't exactly stepped up to address the failure of Phase II with candor and authority.
States are under tremendous budgetary pressure now- much worse than when NM partnered with BMOD. I gotta' wonder how many of these states will now be willing to lay out any resources for an outfit like BMOD.
Even if you are a true believer that the test will eventually work as the company forecasts, IMO you'll have every chance to buy as many shares as you want under .20 within the next 9 months to a year.
you're crazy!!
What scares me more about AVNR over the next couple of weeks is the possibility of a selling of shares by the company at under 3$ a pop.
You'll recall ALXA sold a boatload of shares at 2.70 when they were trading over 3$. Guess they wanted a bit of financial insurance if the FDA gave the thumbs down....good move as it turns out.
AVNR recently registered shares- I have a 2.96 stink bid in in case they decide to raise a little cash pre-FDA
You gotta believe!!! Thanks for the lift after my BMOD soiled the sheets last week. Especially appreciate those CAPS!!
I suspect that once the bottom is in, this will trade in a tight range of a few cents while we wait for news. Sound familiar? Except that it'll be a range significantly south of the .16-.22 that we "enjoyed" until the news hit this week.
It'll also be interesting to see if any of the bigger investors who bought in at .16 and higher see this as a fantastic buying op and add to their positions.
Thanks for the reply. My understanding of the situation is actually very much the same as what you outlined. Here's my concern:
From the time the second cohort was added, a year has past. And the results of the year's work are that the company only now has revealed that they had to exclude samples from a significant number of participants. What is a significant proportion of 20? With 160 individuals screened in Phase 2, not having an adequate buffer to support the results is inexplicable.
And what exactly were the results? The PR says nothing about what the phase 2 study actually found.
With so much supposed expertise on board at BMOD, it's pretty ludicrous to fault the FDA. They just make the rules. Companies choose to play by them or not.
Bottom line: at no time did the company indicate procedural problems with the second cohort, and this borders on fraud IMO. To the contrary, they've as much as said all along that it was just a matter of routine analysis and collation of data from the study. And according to Cousins:
Video #1- CEO says “very good accuracy” go to the 2 minute mark on the video---